Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
52 hedge funds and large institutions have $209M invested in Sigilon Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 11 closing their positions.
0% more funds holding
Funds holding: 52 → 52 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
52% less capital invested
Capital invested by funds: $438M → $209M (-$230M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7.36M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$4.29M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$1.79M |
| 5 |
BlackRock
New York
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$19M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$7.7M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$2.76M |
| 4 |
Millennium Management
New York
|
-$2.33M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$782K |
SGTX Hedge Fund Activity: Q2 2021 in Review
52 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q2 2021, worth a combined $209M — down 52% from $438M a quarter earlier.
Fund positioning in SGTX was balanced in Q2 2021: 11 funds opened new positions, 11 closed out, 16 added to existing stakes and 16 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $7.36M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $19M sold.
- 52 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $209M of Sigilon Therapeutics, Inc. Common Stock stock for Q2 2021, down 52% quarter-over-quarter.
- 11 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q2 2021 and 11 closed out, a net change of 0 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q2 2021 was Morgan Stanley, an estimated $7.36M added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q2 2021 was Avidity Partners Management, an estimated $19M sold.
Based on aggregated 13F filings for Q2 2021.